SEACOAST 1- SEdAtion With COllAteral Support in Endovascular Therapy for Acute Ischemic Stroke

NCT ID: NCT03737786

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-11-28
• Study Completion Date: 2026-12-31

Brief Summary

SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, with different forms of GA in patients with acute ischemic stroke due to anterior circulation large vessel occlusion (LVO) undergoing mechanical thrombectomy. The study compares GA with normocarbia (GAN) versus GA with mild hypercarbia (GAH), with a primary outcome of collateral robustness at measured at catheter angiography and clinical efficacy as secondary outcome. It is anticipated that the SEACOAST 1 will be followed by a larger, pivotal trial, SEACOAST 2, with primary clinical endpoints, in which the best method of GA identified in SEACOAST 1 is compared with the alternative strategy of anesthesia care (MAC) with minimal or no sedation. The current study focuses uppn SEACOAST 1, which is to be conducted in University of California, Los Angeles Ronald Reagan Medical Center and Santa Monica Medical Center. All acute stroke patients who arrive to one of these two stroke centers and are deemed eligible for thrombectomy will be considered for the proposed study. Physician-investigators will determine study eligibility. Informed consent to participate in the study will be obtained from legally authorized representatives or competent patients. For non-competent patients without on-scene legally authorize representatives, the consent process will utilize enrollment in emergency circumstances with exemption of informed consent (EFIC).

Detailed Description

Study design:

SEACOAST 1 is a prospective, randomized, blinded endpoint trial comparing collateral vigor and clinical outcomes, focusing on two distinct sedation strategies:

1. General anesthesia with mild hypercarbia (GAH) during the sedation up until full revascularization versus

2. General anesthesia with normocarbia (GAN) during the sedation up until full revascularization

Neuroanesthesia protocol, focused on maintenance of baseline BP, avoidance of hypotension during induction, and targeted partial pressure of carbon monoxide (PCO2) levels (normocarbia or mild hypercarbia):

• Anesthesia must not delay target initiation of procedure (groin puncture) of 90 min from ED arrival
• Standard American Society of Anesthesiologists (ASA) monitoring: 5 lead ECG, end-tidal CO2 (ETCO2), Pulse oximeter, BP monitor, Body temperature per esophageal probe, ET gas analyser
• Neuromuscular block (NMB) monitor for depth of neuromuscular blockade
• Arterial line placement is encouraged if it can be inserted within 5 min. Otherwise noninvasive BP per cuff. If arterial line has not been placed prior to induction monitor noninvasive blood pressure (NIBP) every 1 min per cuff until arterial line becomes available.
• BP goals - keep at baseline with goal of no more than 10% drop (last recorded BP prior to induction) and cannot exceed 185/105 if patients received intravenous tissue plasminogen activator (IV TPA).

*BP can be lowered to desired goal only after revascularization as deemed necessary by the neurointerventional physician

• Induction with propofol or etomidate and rocuronium 1.2 mg/kg or succinylcholine
• Short acting vasoactive drugs (Phenylephrine, Ephedrine, Esmolol, Clevidipine) should be readily available to maintain BP in the predefined range throughout procedure. Phenylephrine drip recommended to maintain BP
• Anesthesia maintenance with volatile anesthetic and fentanyl; doses to be titrated to BP per anesthesiologist
• Qualitative end-tidal CO2 (ETCO2) measurement
• Immediately upon groin puncture interventionalist will provide blood gas sample to test arterial C02

A. Normocarbia arm:

Controlled ventilation with PCO2 levels 40 (±5%)

B. Mild hypercarbia arm:

Controlled ventilation with PCO2 levels 50 (±5%)

• Normalize PCO2 levels to 40 (±5%) immediately after adequate revascularization (TICI 2B)
• Baseline arterial blood gas values for correlation/correction with PCO2 level detected on ETCO2 measurements
• Mandatory extubation attempt within 60 minutes after procedure completion. Reasons for failed extubation should be documented

Conditions

Acute Stroke

Keywords

large vessel occlusion; anesthesia; thrombectomy; acute ischemic stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

GA with mild hypercarbia (GAH)

Controlled ventilation with target end-tidal CO2 levels 50 (±5%)

Group Type: ACTIVE_COMPARATOR

Tight control of end-tidal CO2 levels

Intervention Type: OTHER

The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation

GA with normocarbia (GAN)

Controlled ventilation with target end-tidal CO2 levels 40 (±5%)

Group Type: ACTIVE_COMPARATOR

Tight control of end-tidal CO2 levels

Intervention Type: OTHER

The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation

Interventions

Tight control of end-tidal CO2 levels

The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age ≥18

2. NIHSS ≥ 6 within 0-16h or NIHSS ≥ 10 within 16-24h

3. Anterior circulation large vessel occlusion (ICA, M1, M2)

4. ASPECTS score ≥ 6 within the first 6h, or DEFUSE trial imaging criteria within 6-16h; or DAWN trial clinical/imaging mismatch criteria within 16-24h

5. Premorbid modified Rankin Scale (mRS) 0-2

6. Patient deemed candidate for mechanical thrombectomy with anticipated groin puncture within 24 hours of last known well and within 90 min of ED arrival

Exclusion Criteria

1. Intubation in ED prior to anesthesiologist evaluation, or intubation for any other medical reason other than planned thrombectomy

2. Rapid neurological improvement, suggestive of revascularization

3. Known serious sensitivity to radiographic contrast agents.

4. Current participation in another investigational drug or device treatment study.

5. Renal Failure as defined by a serum creatinine > 2.0 mg/dl (or 176.8 μmol/l) or Glomerular Filtration Rate [GFR] < 30.

6. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason.

7. Life expectancy of less than 90 days.

8. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal

9. Subject with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow up assessments.

10. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol (defined as regular or daily consumption of more than 4 alcoholic drinks per day.

11. Septic or cardiogenic shock with severe life-threatening hypotension

1. Computed tomography (CT) or Magnetic Resonance Imaging (MRI) evidence of acute intracranial hemorrhage on presentation.

2. CT or MRI evidence of mass effect or intracranial tumor (except small meningioma).

3. CT showing hypodensity or MRI showing hyperintensity involving greater than 1/3 of the middle cerebral artery (MCA) territory (or in other territories, >100 cc of tissue) on presentation.

4. Baseline non contrast CT or DWI MRI evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) < 6

5. CT or MRI evidence that ischemia is not in anterior circulation distribution.

6. Imaging evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.).

1. History of Malignant Hyperthermia

2. History of allergic reaction/anaphylaxis to anesthetic drugs

3. Inability to tolerate supine position (severe CHF)

4. Chronic O2 dependence or any other known pulmonary condition that might lead to difficult extubation and prolonged mechanical ventilation including known pulmonary hypertension

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 110 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Southern California

OTHER

Sponsor Role: collaborator

University of California, Los Angeles

OTHER

Sponsor Role: lead

Responsible Party

Radoslav Raychev

Assistant Clinical Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Radoslav Raychev, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

UCLA Stroke Center

Los Angeles, California, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Radoslav Raychev, MD

Role: CONTACT

Phone: 310-794-6379

Email: rraychev@mednet.ucla.edu

Gilda Avila

Role: CONTACT

Phone: 310-825-1806

Email: GAvila@mednet.ucla.edu

Facility Contacts

Radoslav Raychev, MD

Role: primary

Gilda Avila

Role: backup

References

Tosello R, Riera R, Tosello G, Clezar CN, Amorim JE, Vasconcelos V, Joao BB, Flumignan RL. Type of anaesthesia for acute ischaemic stroke endovascular treatment. Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2.

Reference Type: DERIVED

PMID: 35857365 (View on PubMed)

Other Identifiers

IRB#18-001454

Identifier Type: -

Identifier Source: org_study_id